[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-herpetic-neuralgia-phn\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-herpetic-neuralgia-phn":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100602475","transcutaneous-auricular-vagus-nerve-stimulation-on-post-herpetic-neuralgia-100602475",false,"NCT07123987","Transcutaneous Auricular Vagus Nerve Stimulation on Post-Herpetic Neuralgia","Inclusion Criteria:\n\nAdults aged 35-65 years diagnosed with PHN. Persistent pain for at least 3 months after herpes zoster infection. Only patients who sign the informed consent form will be included.\n\nExclusion Criteria:\n\nContraindications to taVNS such as:\n\n1. pregnancy;\n2. active implants (e.g., pacemakers, cochlear implants) or brain shunts;\n3. previous neurological or psychiatric diagnoses;\n4. history of addiction or substance abuse;\n5. history of trauma and\u002For brain surgery;\n6. cardiac disease;\n7. acute or chronic use of medications and\u002For illicit drugs;\n8. susceptibility to headaches and seizures. Severe cognitive impairment. Other chronic pain conditions.","ALL","35 Years","65 Years",{"count":19,"type":20},34,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) in the treatment of patients with post-herpetic neuralgia (PHN). Participants will receive taVNS in addition to standard care. The study aims to determine whether taVNS can provide significant pain relief and improve quality of life in PHN patients.",[26],"Post Herpetic Neuralgia (PHN)",[28,29,30,31,32,33,34,35],"Post-Herpetic Neuralgia","Neuropathic Pain","Herpes Zoster","Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)","Non-invasive Neuromodulation","Chronic Pain Management","Pain Relief","Randomized Controlled Trial","RECRUITING","2026-03-16",{"date":39,"type":40},"2026-03-18","ACTUAL",{"date":42,"type":40},"2025-09-07",{"date":44,"type":20},"2026-09-09",{"name":46,"class":47},"Mohamed Hosny Ismail Easa","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":48},"100590592","comparative-efficacy-of-pregabalin-and-lacosamide-in-patients-with-herpes-zoster-and-post-herpetic-neuralgia-100590592","NCT06969417","Comparative Efficacy of Pregabalin and Lacosamide in Patients With Herpes Zoster and Post Herpetic Neuralgia","Inclusion Criteria:\n\n* Diagnosed cases of herpes zoster suffering from postherpetic neuralgia\n* Ages: 18 to 50\n* Both male and female\n\nExclusion Criteria:\n\n* Lack of consent\n* Patient already taking pain killers for post herpetic neuralgia\n* Patients suffering from other systemic illness","18 Years","50 Years",{"count":58,"type":20},50,[23],"Post-herpetic neuralgia (PHN) is the most significant complication of herpes zoster caused by reactivation of latent Varicella-Zoster virus (VZV). PHN is characterized by neuropathic pain lasting beyond the resolution of the rashes. Post herpetic neuralgia (PHN) represents a potentially debilitating and often undertreated form of neuropathic pain that disproportionately affects vulnerable populations, including the elderly and the immunocompromised. PHN pain is typically localized, unilateral and chronic, but may be constant, intermittent, spontaneous and\u002For evoked. PHN is likely to interfere with sleep and daily activities.\n\nPregabalin is a gabapentinoid licenced for treatment of neurological disorders. It is one of the earlier drugs approved by the US Food and Drug Administration (2004) for the treatment of painful diabetic neuropathy and postherpetic neuralgia (PHN). Lacosamide (LCM) was approved in 2008 in the European Union and in the United States as adjunctive therapy for the treatment of focal-onset seizures with or without secondary generalization in adults and adolescents with epilepsy. Its efficacy has also been proven in neuropathic pain.\n\nAlthough Pregabalin and Lacosamide have proven effective in various neuropathic pain disorder, comparative studies specifically for PHN remain scarce. This study aims to compare the efficacy of Pregabalin and Lacosamide in PHN patients, addressing the current gap in literature and providing clinically relevant insights to optimize treatment selection.",[62,26],"Herpes Zoster (HZ)","2025-05-13",{"date":65,"type":40},"2025-05-14",{"date":67,"type":40},"2025-04-10",{"date":69,"type":20},"2025-09-30",{"name":71,"class":72},"CMH Kharian Medical College","OTHER_GOV","Post-Herpetic Neuralgia (PHN)"]